Electromed Stock (AMEX:ELMD), Trade Ideas

Electromed

Electromed Inc is a United States-based company that develops, manufactures, markets and sells innovative products that provide airway clearance therapy, including the SmartVest Airway Clearance System and related products, to patients with compromised pulmonary function with a commitment to excellence and compassionate service. The SmartVest System features a programmable air pulse generator, a therapy garment worn over the upper body and a connecting hose, which together provide safe, comfortable, and effective airway clearance therapy.

News

Penny Stocks

Pre-Market Outlook

Markets

Movers

Trading Ideas

AGLE

ANIX

ARQT

BBBY

BEEM

BNTC

CBAT

CCCC

CFFN

CGEN

CODX

CTIC

ELMD

ENLV

EVGN

GDOT

GRNQ

GRTX

HGBL

HMHC

HYLN

Hycroft Mining Holding Corporation - Class A Common Stock

HYMC

ITRM

Janus Henderson Group plc Ordinary Shares

KZIA

LONE

MESO

MICT

NAKD

NEOG

NNOX

NRIX

PDLI

PLSE

PRPH

RNST

SLDB

SRRK

TARA

THRY

TNAV

TWLO

VJET

VVPR

XTNT

Gainers


	Xtant Medical Holdings, Inc. (NYSE: XTNT) shares climbed 91.4% to close at $1.57 on Friday after the company announced the closing of debt restructuring.


58 Biggest Movers From Friday

Intraday Update

ADIL

APOP

BORR

BOXL

GERN

YALA

Gainers


	Xtant Medical Holdings, Inc. (NYSE: XTNT) jumped 112.1% to $1.74 after the company announced the closing of debt restructuring.


44 Stocks Moving In Friday&#39;s Mid-Day Session

AESE

AEYE

AKER

AMTX

AUTO

AVGR

BIGC

BLNK

BNTX

BPTH

CALT

CATB

CATO

CLPS

CLXT

CMBM

CYRX

EYPT

GASS

GEVO

HARP

HJLI

HTGM

IFMK

KELYB

KEYS

KIRK

KOSS

KYMR

LMPX

MARA

MOBL

MOGU

NMTR

OSUR

Citigourp Global Markets 2% Protected Notes Linked To The Djia

PEIX

PIXY

PRPO

PVAC

SHSP

SMRT

TOPS

UONE

VUZI

Gainers


	Kymera Therapeutics, Inc. (NASDAQ: KYMR) shares gained 66.3% to close at $33.26 on Friday after the company priced its 8.684 million share IPO at $20 per share.


60 Biggest Movers From Friday

Electromed Inc

<h3>Gainers</h3>
<ul>
<li>Cogent Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COGT#NASDAQ">COGT</a>) stock increased by 64.0% to $8.96 during Wednesday's regular session. The company's market cap stands at $771.2 million. </li>
<li>Larimar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRMR#NASDAQ">LRMR</a>) shares increased by 45.53% to $12.72. The company's market cap stands at $558.4 million. </li>
<li>BioXcel Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTAI#NASDAQ">BTAI</a>) stock rose 35.2% to $3.33. The company's market cap stands at $101.0 million. </li>
<li>Greenwich LifeSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLSI#NASDAQ">GLSI</a>) stock moved upwards by 31.26% to $10.91. The company's market cap stands at $140.1 million. </li>
<li>Electromed (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ELMD#AMEX">ELMD</a>) stock rose 22.61% to $12.43. The market value of their outstanding shares is at $106.6 million. As per the news, the Q2 earnings report came out yesterday. </li>
<li>Puma Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBYI#NASDAQ">PBYI</a>) shares moved upwards by 18.76% to $7.38. The market value of their outstanding shares is at $350.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Anitra (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AZTR#AMEX">AZTR</a>) stock declined by 71.3% to $0.25 during Wednesday's regular session. The market value of their outstanding shares is at $3.0 million. </li>
<li>QuidelOrtho (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QDEL#NASDAQ">QDEL</a>) stock fell 29.1% to $47.34. The company's market cap stands at $3.1 billion. As per the news, the Q4 earnings report came out yesterday. </li>
<li>NeuroOne Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMTC#NASDAQ">NMTC</a>) shares decreased by 16.35% to $1.18. The company's market cap stands at $30.5 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Renalytix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNLX#NASDAQ">RNLX</a>) shares fell 14.9% to $1.2. The company's market cap stands at $59.9 million. </li>
<li>Sientra (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIEN#NASDAQ">SIEN</a>) shares declined by 14.22% to $0.17. The company's market cap stands at $2.0 million. </li>
<li>Sunshine Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBFM#NASDAQ">SBFM</a>) shares declined by 12.51% to $0.06. The company's market cap stands at $1.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AZTR

BTAI

COGT

GLSI

Larimar Therapeutics, Inc. - Common Stock

LRMR

NMTC

PBYI

QDEL

RNLX

SBFM

SIEN

12 Health Care Stocks Moving In Wednesday's Intraday Session

WIIM

Electromed shares are trading higher after the company reported better-than-expected Q2 results.

Electromed (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ELMD#AMEX">ELMD</a>) reported its Q2 earnings results on Tuesday, February 13, 2024 at 04:05 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Electromed beat estimated earnings by 90.0%, reporting an EPS of $0.19 versus an estimate of $0.1.
Revenue was up $1.96 million from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company missed on EPS by $0.08 which was followed by a 2.09% increase in the share price the next day.
Here's a look at Electromed's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.10</td>
<td></td>
<td>0.10</td>
<td>0.03</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.02</td>
<td>0.12</td>
<td>0.12</td>
<td>0.11</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>12.60M</td>
<td>12.80M</td>
<td>12.05M</td>
<td>11.05M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>12.32M</td>
<td>13.61M</td>
<td>12.07M</td>
<td>11.73M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Electromed <a href="https://www.benzinga.com/quote/ELMD/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

Recap: Electromed Q2 Earnings

Electromed (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ELMD#AMEX">ELMD</a>) reported quarterly earnings of $0.19 per share which beat the analyst consensus estimate of $0.10 by 90 percent. This is a 72.73 percent increase over earnings of $0.11 per share from the same period last year. The company reported quarterly sales of $13.69 million which beat the analyst consensus estimate of $13.30 million by 2.92 percent. This is a 16.71 percent increase over sales of $11.73 million the same period last year.

Electromed Q2 Gaap EPS $0.19 Beats $0.10 Estimate, Sales $13.69M Beat $13.30M Estimate

ABNB

AKAM

AKTS

ALSN

ANGI

ATOM

BENF

BFAM

BIIB

BRKR

CART

CHCT

CRSR

CTHR

DDOG

DENN

DNUT

ENTG

FELE

GCMG

GDDY

GNSS

GORO

HOOD

INCY

INMD

INVH

IOSP

IPGP

KTOS

LCII

LDOS

LOPE

LYFT

MODG

NTWK

REZI

ROIV

RUSHA

RUSHB

SHOP

SITC

SITM

SMWB

SSNC

STAG

TYGO

UFCS

UPST

USAC

VTGN

Earnings Scheduled For February 13, 2024

Electromed (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ELMD#AMEX">ELMD</a>) is set to give its latest quarterly earnings report on Tuesday, 2024-02-13. Here's what investors need to know before the announcement.
Analysts estimate that Electromed will report an earnings per share (EPS) of $0.10. 
Electromed bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Past Earnings Performance</h3>
Last quarter the company missed EPS by $0.08, which was followed by a 2.09% increase in the share price the next day.
Here's a look at Electromed's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.10</td>
<td></td>
<td>0.10</td>
<td>0.03</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.02</td>
<td>0.12</td>
<td>0.12</td>
<td>0.11</td>
</tr>
<tr>
<td>Price Change %</td>
<td>2.09%</td>
<td>10.59%</td>
<td>12.02%</td>
<td>5.68%</td>
</tr>
</tbody>
</table>

<h3>Stock Performance</h3>
Shares of Electromed were trading at $10.38 as of February 09. Over the last 52-week period, shares are down 10.97%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/ELMD/earnings">To track all earnings releases for Electromed visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Outlook For Electromed

Biotech

Contracts

General

Electromed  Entered Into Distribution Agreement With Marathon Medical Corp; Financial Terms Not Disclosed

Bradley Nagel, Chief Financial Officer at Electromed (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ELMD#AMEX">ELMD</a>), reported a large acquisition of company stock options on November 14, according to a new SEC filing.
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0001488917/000143774923032054//Archives/edgar/data/1488917/000143774923032054/0001437749-23-032054-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday showed that Nagel, Chief Financial Officer at Electromed, a company in the Health Care sector, was just awarded stock options worth 6,500 shares of ELMD. The options give Nagel the right to buy the company's stock at $10.25 per share.
Electromed shares are trading down 0.0% at $10.52 at the time of this writing on Wednesday morning. Since the current price is $10.52, this makes Nagel's 6,500 shares worth $68,380.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Importance of Insider Transactions</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however, they can be an important factor for an investor to consider.
In legal terms, an "insider" refers to any officer, director, or beneficial owner of more than ten percent of a company's equity securities registered under Section 12 of the Securities Exchange Act of 1934. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>Transaction Codes To Focus On</h3>
<a href="https://www.benzinga.com/money/investing-tools">Investors</a> prefer focusing on transactions that take place in the open market, indicated in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S indicates a sale. Transaction code C indicates the conversion of an option, and transaction code A indicates the insider may have been forced to sell shares in order to receive compensation that had been promised upon being hired by the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001488917">Check Out The Full List Of Electromed's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Chief Financial Officer at Electromed Acquires Company Stock Options Worth 6,500 Shares

Electromed (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ELMD#AMEX">ELMD</a>) reported quarterly earnings of $0.02 per share which missed the analyst consensus estimate of $0.10 by 80 percent. This is a 100 percent increase over earnings of $0.01 per share from the same period last year. The company reported quarterly sales of $12.32 million which missed the analyst consensus estimate of $12.60 million by 2.19 percent. This is a 15.63 percent increase over sales of $10.66 million the same period last year.

Electromed Q1 2024 EPS $0.02 Misses $0.10 Estimate, Sales $12.32M Miss $12.60M Estimate

Electromed (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ELMD#AMEX">ELMD</a>) reported quarterly earnings of $0.12 per share. This is a 200 percent increase over earnings of $0.04 per share from the same period last year. The company reported quarterly sales of $13.60 million which beat the analyst consensus estimate of $12.80 million by 6.25 percent. This is a 20.70 percent increase over sales of $11.27 million the same period last year.

Earnings Beats

Electromed Q4 EPS $0.12 Up From $0.04 YoY, Sales $13.60M Beat $12.80M Estimate